EC Number   |
Application |
Reference |
|---|
    3.5.2.3 | drug development |
the essential enzyme is a target for antibacterial drug design |
-, 735213 |
| 3.5.2.3 | drug development |
the substantial difference between bacterial and mammalian DHOs makes the bacterial enzyme a promising drug target for disrupting bacterial growth and thus an important candidate to evaluate as a response to antimicrobial resistance on a molecular level |
-, 756957 |
| 3.5.2.3 | medicine |
activation of the cardioprotective agent dexrazoxane by the enzyme in heart, mechanism |
650954 |
| 3.5.2.3 | medicine |
involved in metabolism of the cardioprotective druc dexrazoxane |
697580 |
| 3.5.2.3 | synthesis |
growth conditions which maintain DHOase overproduction require supplementation of Yeast Carbon Base with asparagines 5 g/l, glucose 20 g/l at pH 5.5. In this medium DHOase activity decreases with time, thus in terms of DHOase yield, the best time for harvesting cells is reached after 30 to 38 h of growth |
710785 |
